Stock Analiz

Orthopediatrics Corp. KIDS

Medical/Dental Instruments · IPO 2017 · data as of November 13, 2026

$32.35Market cap $845M
Open the interactive analysis →

Orthopediatrics Corp. (KIDS) is a healthcare company listed in the US with a market value of about $845M. In the twelve months to September 30, 2026 it had revenue of $264M and net income of -$34M, a net margin of -12.8%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 265.6, 5-year revenue growth of 27% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.

About Orthopediatrics

Orthopediatrics is listed in the US and classified in medical/dental instruments, IPO year 2017. Revenue went from $31M in 2015 to $236M in 2025, growth of about 22.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 12% over three years (dilution for shareholders). It spends 4% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF265.6
P/S3.2
P/B2.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield0.4%
Shareholder yield0.0%
Intrinsic value vs. price−84%

Growth and quality

Revenue growth (1 yr)15.4%
Revenue growth (5 yrs, per year)27.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-13.0%
ROIC (5-yr avg.)-6.7%
Profitable years (of last 10)1
Years paying a dividend1

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$264M$236M$205M$149M$122M$98M$71M$73M$58M$46M$37M
Net income-$34M-$40M-$38M-$21M$1M-$16M-$33M-$14M-$12M-$9M-$7M
Free cash flow$3M-$16M-$41M-$44M-$32M-$21M-$29M-$30M-$21M-$12M-$5M
EPS (diluted)$-1.43$-1.69$-1.64$-0.92$0.06$-0.84$-1.82$-0.94$-0.96$-5.86$-7.14
Net margin-12.8%-16.8%-18.5%-14.1%1.0%-16.6%-46.4%-18.9%-20.9%-19.6%-17.6%
ROIC—-6.7%-7.2%-6.8%-5.3%-7.4%-11.1%-5.4%-9.3%-8.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $30.75, 5% below the current price; targets range from $27.00 to $38.00; the consensus rating is “none”; expected EPS is $-1.09 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Orthopediatrics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Orthopediatrics pay a dividend?

Not currently.

Is Orthopediatrics a good stock to buy?

We do not give buy or sell advice. Orthopediatrics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.